scholarly article | Q13442814 |
P2093 | author name string | Karri Utriainen | |
Airi Jussila | |||
Urpo Nieminen | |||
Taina Sipponen | |||
Markku Heikkinen | |||
Christian Nielsen | |||
Taru Hallinen | |||
Erkki Soini | |||
Ritva Koskela | |||
Anja Eberl | |||
Tuire Ilus | |||
Andras Borsi | |||
Veikko Moilanen | |||
Christina Wennerström | |||
Clas-Göran Af Björkesten | |||
Heikki Nuutinen | |||
Ilkka Vihriälä | |||
Inka Koskinen | |||
Jyrki Tillonen | |||
Kalle Hakala | |||
Mikko Heikura | |||
Minni R Koivunen | |||
Riikka Nissinen | |||
Ulla-Maija Suhonen | |||
P2860 | cites work | A simple index of Crohn's-disease activity | Q28259898 |
Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease | Q30054715 | ||
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease | Q34255362 | ||
Vedolizumab as induction and maintenance therapy for Crohn's disease | Q34365574 | ||
A systematic review of measurement of endoscopic disease activity and mucosal healing in Crohn's disease: recommendations for clinical trial design | Q35207745 | ||
Treat to target: a proposed new paradigm for the management of Crohn's disease | Q38137614 | ||
Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. | Q38619950 | ||
Long-term Efficacy of Vedolizumab for Crohn's Disease | Q39340730 | ||
Ustekinumab induction and maintenance therapy in refractory Crohn's disease | Q42514321 | ||
Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity | Q46770065 | ||
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort | Q48172992 | ||
Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. | Q48282663 | ||
Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. | Q53658057 | ||
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy. | Q55693561 | ||
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD | Q80838195 | ||
Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population | Q83463037 | ||
Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease | Q89125447 | ||
Safety and effectiveness of ustekinumab for induction of remission in patients with Crohn's disease: A multicenter Israeli study | Q90656440 | ||
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission Rates | Q91329599 | ||
Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort | Q91809503 | ||
Ustekinumab is effective in biological refractory Crohn's disease patients-regardless of approval study selection criteria | Q92300916 | ||
IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease | Q92488525 | ||
Ustekinumab for Crohn's disease: a nationwide real-life cohort study from Finland (FINUSTE) | Q92654305 | ||
Ustekinumab for Crohn's Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort Study | Q92895315 | ||
Real-world short-term effectiveness of ustekinumab in 305 patients with Crohn's disease: results from the ENEIDA registry | Q92925396 | ||
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study | Q93116972 | ||
Ustekinumab: "Real-world" outcomes and potential predictors of nonresponse in treatment-refractory Crohn's disease | Q93184539 | ||
P577 | publication date | 2020-08-28 | |
P1433 | published in | European Journal of Gastroenterology and Hepatology | Q15746143 |
P1476 | title | Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohort |
Search more.